Emerging Class III Antiarrhythmic Agents:Mechanism of Action and Proarrhythmic Potential View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-04

AUTHORS

Lawrence A. Nair, Augustus O. Grant

ABSTRACT

The goal of developing an antiarrhythmic agent effective against malignant ventricular arrhythmias while maintaining a low side-effect profile remains elusive. The class III drugs amiodarone and sotalol are the best available agents. However, both drugs possess properties outside the realm of a pure class III effect, and their use is limited by a variety of dose-related side effects. There are several drugs with more selective class III properties currently in development. This review provides an overview of the optimal characteristics of an effective theoretical class III drug and a summary of the properties of a number of class III drugs under active investigation. An ideal class III antiarrhythmic agent for a reentrant arrhythmia should provide use-dependent prolongation of the action potential duration with slow onset and rapid offset kinetics. This drug would prolong the effective refractory period of cardiac tissue selectively at the rapid heart rates achieved during ventricular tachycardia or fibrillation with a delayed onset of action, and a rapid resolution of its effects on resumption of physiologic heart rates. With little effect on the refractory period at normal or slow heart rates, the ability to induce torsade de pointes would be lessened. In contrast to these ideal properties, most currently available and investigational agents have a reverse use-dependent effect on the action potential duration, producing more effects on the refractory period at slower heart rates. This property results in part from preferential block of the rapidly activating component of the delayed rectifier potassium channel (I_Kr), with little or no effect on the slowly activating component (I_Ks). The development of a drug with favorable blocking kinetics that selectively blocks I_Ks may result in lower proarrhythmic events while still maintaining effective antiarrhythmic properties. More... »

PAGES

149-167

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1007784814823

DOI

http://dx.doi.org/10.1023/a:1007784814823

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043450659

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9140692


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Arrhythmia Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arrhythmias, Cardiac", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Duke University Medical Center, Durham, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.414179.e", 
          "name": [
            "Department of Medicine, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nair", 
        "givenName": "Lawrence A.", 
        "id": "sg:person.0742051110.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742051110.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Duke University Medical Center, Durham, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.414179.e", 
          "name": [
            "Department of Medicine, Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grant", 
        "givenName": "Augustus O.", 
        "id": "sg:person.01130565260.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130565260.31"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00877629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032432823", 
          "https://doi.org/10.1007/bf00877629"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00877626", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006392561", 
          "https://doi.org/10.1007/bf00877626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00581631", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035526856", 
          "https://doi.org/10.1007/bf00581631"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01258466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031359380", 
          "https://doi.org/10.1007/bf01258466"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00878513", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022359332", 
          "https://doi.org/10.1007/bf00878513"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-4615-7858-1_9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016316955", 
          "https://doi.org/10.1007/978-1-4615-7858-1_9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1997-04", 
    "datePublishedReg": "1997-04-01", 
    "description": "The goal of developing an antiarrhythmic agent effective against malignant ventricular arrhythmias while maintaining a low side-effect profile remains elusive. The class III drugs amiodarone and sotalol are the best available agents. However, both drugs possess properties outside the realm of a pure class III effect, and their use is limited by a variety of dose-related side effects. There are several drugs with more selective class III properties currently in development. This review provides an overview of the optimal characteristics of an effective theoretical class III drug and a summary of the properties of a number of class III drugs under active investigation. An ideal class III antiarrhythmic agent for a reentrant arrhythmia should provide use-dependent prolongation of the action potential duration with slow onset and rapid offset kinetics. This drug would prolong the effective refractory period of cardiac tissue selectively at the rapid heart rates achieved during ventricular tachycardia or fibrillation with a delayed onset of action, and a rapid resolution of its effects on resumption of physiologic heart rates. With little effect on the refractory period at normal or slow heart rates, the ability to induce torsade de pointes would be lessened. In contrast to these ideal properties, most currently available and investigational agents have a reverse use-dependent effect on the action potential duration, producing more effects on the refractory period at slower heart rates. This property results in part from preferential block of the rapidly activating component of the delayed rectifier potassium channel (I_Kr), with little or no effect on the slowly activating component (I_Ks). The development of a drug with favorable blocking kinetics that selectively blocks I_Ks may result in lower proarrhythmic events while still maintaining effective antiarrhythmic properties.", 
    "genre": "article", 
    "id": "sg:pub.10.1023/a:1007784814823", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2531253", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1097576", 
        "issn": [
          "0920-3206", 
          "1573-7241"
        ], 
        "name": "Cardiovascular Drugs and Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "keywords": [
      "class III antiarrhythmic agent", 
      "slower heart rate", 
      "action potential duration", 
      "heart rate", 
      "antiarrhythmic agents", 
      "class III drugs", 
      "refractory period", 
      "potential duration", 
      "low side effect profile", 
      "reverse use-dependent effects", 
      "dose-related side effects", 
      "best available agents", 
      "use-dependent prolongation", 
      "side effect profile", 
      "class III effects", 
      "malignant ventricular arrhythmias", 
      "onset of action", 
      "effective refractory period", 
      "use-dependent effects", 
      "rapid heart rate", 
      "class III properties", 
      "rectifier potassium channel", 
      "mechanism of action", 
      "proarrhythmic events", 
      "ventricular arrhythmias", 
      "proarrhythmic potential", 
      "investigational agents", 
      "ventricular tachycardia", 
      "antiarrhythmic properties", 
      "offset kinetics", 
      "rapid resolution", 
      "physiologic heart rates", 
      "preferential block", 
      "available agents", 
      "slow onset", 
      "side effects", 
      "drug amiodarone", 
      "reentrant arrhythmias", 
      "potassium channels", 
      "drugs", 
      "cardiac tissue", 
      "III effects", 
      "active investigation", 
      "arrhythmias", 
      "onset", 
      "agents", 
      "duration", 
      "torsades", 
      "amiodarone", 
      "tachycardia", 
      "pointes", 
      "fibrillation", 
      "sotalol", 
      "period", 
      "prolongation", 
      "rate", 
      "effect", 
      "little effect", 
      "tissue", 
      "action", 
      "resumption", 
      "review", 
      "more effect", 
      "development", 
      "summary", 
      "events", 
      "contrast", 
      "profile", 
      "mechanism", 
      "use", 
      "ability", 
      "optimal characteristics", 
      "components", 
      "number", 
      "ideal properties", 
      "investigation", 
      "potential", 
      "overview", 
      "variety", 
      "characteristics", 
      "goal", 
      "part", 
      "block", 
      "kinetics", 
      "channels", 
      "resolution", 
      "properties", 
      "realm"
    ], 
    "name": "Emerging Class III Antiarrhythmic Agents:Mechanism of Action and Proarrhythmic Potential", 
    "pagination": "149-167", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043450659"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1007784814823"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9140692"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1007784814823", 
      "https://app.dimensions.ai/details/publication/pub.1043450659"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_267.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1023/a:1007784814823"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1007784814823'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1007784814823'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1007784814823'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1007784814823'


 

This table displays all metadata directly associated to this object as RDF triples.

202 TRIPLES      21 PREDICATES      125 URIs      110 LITERALS      11 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1007784814823 schema:about N12a2378b05ed4cf7a0597c581859e3fc
2 N2663ac33570643d8afc01d08cb7b61b5
3 N4ab4ce356e9d46eda541814aba38a531
4 Nbdbce6c5ba14463ab98e647cabbd1a96
5 anzsrc-for:11
6 anzsrc-for:1102
7 anzsrc-for:1115
8 schema:author N08c589d821ee4f87bf7e9ddf2a5e09ca
9 schema:citation sg:pub.10.1007/978-1-4615-7858-1_9
10 sg:pub.10.1007/bf00581631
11 sg:pub.10.1007/bf00877626
12 sg:pub.10.1007/bf00877629
13 sg:pub.10.1007/bf00878513
14 sg:pub.10.1007/bf01258466
15 schema:datePublished 1997-04
16 schema:datePublishedReg 1997-04-01
17 schema:description The goal of developing an antiarrhythmic agent effective against malignant ventricular arrhythmias while maintaining a low side-effect profile remains elusive. The class III drugs amiodarone and sotalol are the best available agents. However, both drugs possess properties outside the realm of a pure class III effect, and their use is limited by a variety of dose-related side effects. There are several drugs with more selective class III properties currently in development. This review provides an overview of the optimal characteristics of an effective theoretical class III drug and a summary of the properties of a number of class III drugs under active investigation. An ideal class III antiarrhythmic agent for a reentrant arrhythmia should provide use-dependent prolongation of the action potential duration with slow onset and rapid offset kinetics. This drug would prolong the effective refractory period of cardiac tissue selectively at the rapid heart rates achieved during ventricular tachycardia or fibrillation with a delayed onset of action, and a rapid resolution of its effects on resumption of physiologic heart rates. With little effect on the refractory period at normal or slow heart rates, the ability to induce torsade de pointes would be lessened. In contrast to these ideal properties, most currently available and investigational agents have a reverse use-dependent effect on the action potential duration, producing more effects on the refractory period at slower heart rates. This property results in part from preferential block of the rapidly activating component of the delayed rectifier potassium channel (I_Kr), with little or no effect on the slowly activating component (I_Ks). The development of a drug with favorable blocking kinetics that selectively blocks I_Ks may result in lower proarrhythmic events while still maintaining effective antiarrhythmic properties.
18 schema:genre article
19 schema:isAccessibleForFree false
20 schema:isPartOf Na5639b36490b427894781ca79d7a8868
21 Ne344373068114315b8dd793ae63aac01
22 sg:journal.1097576
23 schema:keywords III effects
24 ability
25 action
26 action potential duration
27 active investigation
28 agents
29 amiodarone
30 antiarrhythmic agents
31 antiarrhythmic properties
32 arrhythmias
33 available agents
34 best available agents
35 block
36 cardiac tissue
37 channels
38 characteristics
39 class III antiarrhythmic agent
40 class III drugs
41 class III effects
42 class III properties
43 components
44 contrast
45 development
46 dose-related side effects
47 drug amiodarone
48 drugs
49 duration
50 effect
51 effective refractory period
52 events
53 fibrillation
54 goal
55 heart rate
56 ideal properties
57 investigation
58 investigational agents
59 kinetics
60 little effect
61 low side effect profile
62 malignant ventricular arrhythmias
63 mechanism
64 mechanism of action
65 more effect
66 number
67 offset kinetics
68 onset
69 onset of action
70 optimal characteristics
71 overview
72 part
73 period
74 physiologic heart rates
75 pointes
76 potassium channels
77 potential
78 potential duration
79 preferential block
80 proarrhythmic events
81 proarrhythmic potential
82 profile
83 prolongation
84 properties
85 rapid heart rate
86 rapid resolution
87 rate
88 realm
89 rectifier potassium channel
90 reentrant arrhythmias
91 refractory period
92 resolution
93 resumption
94 reverse use-dependent effects
95 review
96 side effect profile
97 side effects
98 slow onset
99 slower heart rate
100 sotalol
101 summary
102 tachycardia
103 tissue
104 torsades
105 use
106 use-dependent effects
107 use-dependent prolongation
108 variety
109 ventricular arrhythmias
110 ventricular tachycardia
111 schema:name Emerging Class III Antiarrhythmic Agents:Mechanism of Action and Proarrhythmic Potential
112 schema:pagination 149-167
113 schema:productId N76bad963c0444d54b8c2a6ace61caee8
114 Nb18ab08725c24a4a8b552c21b331bccb
115 Nbad519f1dd944c4cbcc7bf4dec696c0c
116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043450659
117 https://doi.org/10.1023/a:1007784814823
118 schema:sdDatePublished 2022-08-04T16:52
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher Nee291e198d6442f195d2ca1c6a8536d3
121 schema:url https://doi.org/10.1023/a:1007784814823
122 sgo:license sg:explorer/license/
123 sgo:sdDataset articles
124 rdf:type schema:ScholarlyArticle
125 N08c589d821ee4f87bf7e9ddf2a5e09ca rdf:first sg:person.0742051110.01
126 rdf:rest Nd23941d6a3ad48bebd9aab79921427c6
127 N12a2378b05ed4cf7a0597c581859e3fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Humans
129 rdf:type schema:DefinedTerm
130 N2663ac33570643d8afc01d08cb7b61b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Animals
132 rdf:type schema:DefinedTerm
133 N4ab4ce356e9d46eda541814aba38a531 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Arrhythmias, Cardiac
135 rdf:type schema:DefinedTerm
136 N76bad963c0444d54b8c2a6ace61caee8 schema:name dimensions_id
137 schema:value pub.1043450659
138 rdf:type schema:PropertyValue
139 Na5639b36490b427894781ca79d7a8868 schema:issueNumber 2
140 rdf:type schema:PublicationIssue
141 Nb18ab08725c24a4a8b552c21b331bccb schema:name doi
142 schema:value 10.1023/a:1007784814823
143 rdf:type schema:PropertyValue
144 Nbad519f1dd944c4cbcc7bf4dec696c0c schema:name pubmed_id
145 schema:value 9140692
146 rdf:type schema:PropertyValue
147 Nbdbce6c5ba14463ab98e647cabbd1a96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Anti-Arrhythmia Agents
149 rdf:type schema:DefinedTerm
150 Nd23941d6a3ad48bebd9aab79921427c6 rdf:first sg:person.01130565260.31
151 rdf:rest rdf:nil
152 Ne344373068114315b8dd793ae63aac01 schema:volumeNumber 11
153 rdf:type schema:PublicationVolume
154 Nee291e198d6442f195d2ca1c6a8536d3 schema:name Springer Nature - SN SciGraph project
155 rdf:type schema:Organization
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
160 schema:name Cardiorespiratory Medicine and Haematology
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
163 schema:name Pharmacology and Pharmaceutical Sciences
164 rdf:type schema:DefinedTerm
165 sg:grant.2531253 http://pending.schema.org/fundedItem sg:pub.10.1023/a:1007784814823
166 rdf:type schema:MonetaryGrant
167 sg:journal.1097576 schema:issn 0920-3206
168 1573-7241
169 schema:name Cardiovascular Drugs and Therapy
170 schema:publisher Springer Nature
171 rdf:type schema:Periodical
172 sg:person.01130565260.31 schema:affiliation grid-institutes:grid.414179.e
173 schema:familyName Grant
174 schema:givenName Augustus O.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130565260.31
176 rdf:type schema:Person
177 sg:person.0742051110.01 schema:affiliation grid-institutes:grid.414179.e
178 schema:familyName Nair
179 schema:givenName Lawrence A.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742051110.01
181 rdf:type schema:Person
182 sg:pub.10.1007/978-1-4615-7858-1_9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016316955
183 https://doi.org/10.1007/978-1-4615-7858-1_9
184 rdf:type schema:CreativeWork
185 sg:pub.10.1007/bf00581631 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035526856
186 https://doi.org/10.1007/bf00581631
187 rdf:type schema:CreativeWork
188 sg:pub.10.1007/bf00877626 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006392561
189 https://doi.org/10.1007/bf00877626
190 rdf:type schema:CreativeWork
191 sg:pub.10.1007/bf00877629 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032432823
192 https://doi.org/10.1007/bf00877629
193 rdf:type schema:CreativeWork
194 sg:pub.10.1007/bf00878513 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022359332
195 https://doi.org/10.1007/bf00878513
196 rdf:type schema:CreativeWork
197 sg:pub.10.1007/bf01258466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031359380
198 https://doi.org/10.1007/bf01258466
199 rdf:type schema:CreativeWork
200 grid-institutes:grid.414179.e schema:alternateName Department of Medicine, Duke University Medical Center, Durham, NC, USA
201 schema:name Department of Medicine, Duke University Medical Center, Durham, NC, USA
202 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...